Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis
New England Journal of Medicine · 26.09.2024 · 391 (12) · 1119-1129
DOI: 10.1056/nejmoa2314076 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 26.09.2024. Verfasst von Bruce E Sands und 16 weiteren Autor:innen. Beteiligte Einrichtung: From the Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York (B.E.S.); the Departments of Medicine,…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Colitis, Ulcerative, Remission Induction, Tumor Necrosis Factor Ligand Superfamily Member 15. Die Arbeit wurde bisher 105-mal zitiert (Crossref) und nennt 16 Literaturangaben. Gefördert von: Prometheus Biosciences, Inc., a subsidiary of Merck.
Abstract (Originalsprache)
BACKGROUND: Tulisokibart is a tumor necrosis factor-like cytokine 1A (TL1A) monoclonal antibody in development for the treatment of moderately to severely active ulcerative colitis. A genetic-based diagnostic test was designed to identify patients with an increased likelihood of response. METHODS: We randomly assigned patients with glucocorticoid dependence or failure of conventional or advanced therapies for ulcerative colitis to receive intravenous tulisokibart (1000 mg on day 1 and 500 mg at weeks 2, 6, and 10) or placebo. Cohort 1 included patients regardless of status with respect to the test for likelihood of response. Cohort 2 included only patients with a positive test for likelihood of response. The primary analysis was performed in cohort 1; the primary end point was clinical remission at week 12. Patients with a positive test for likelihood of response from cohorts 1 and 2 were combined in prespecified analyses. RESULTS: In cohort 1, a total of 135 patients underwent randomization. A significantly higher percentage of patients who received tulisokibart had clinical remission than those who received placebo (26% vs. 1%; difference, 25 percentage points; 95% confidence interval [CI], 14 to 37; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York (B.E.S.); the Departments of Medicine, Epidemiology, and Biostatistics, Western University, London, ON (B.G.…
ORCID-Profile: Bruce E Sands, Christopher Ma
Förderung
- Prometheus Biosciences, Inc., a subsidiary of Merck
Zitieren
APA
Sands, B. E., Feagan, B. G., Peyrin-Biroulet, L., Danese, S., Rubin, D. T., Laurent, O., Luo, A., Nguyen, D. D., Lu, J., Yen, M., Leszczyszyn, J., Kempiński, R., McGovern, D. P. B., Ma, C., Ritter, T. E., Targan, S., & ARTEMIS-UC Study Group (2024). Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis. New England Journal of Medicine, 391(12), 1119-1129. https://doi.org/10.1056/nejmoa2314076
Vancouver
Sands BE, Feagan BG, Peyrin-Biroulet L, Danese S, Rubin DT, Laurent O, et al. Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis. New England Journal of Medicine. 2024;391(12):1119-1129. doi:10.1056/nejmoa2314076
BibTeX
@article{Sands2024,
author = {Sands, Bruce E and Feagan, Brian G and Peyrin-Biroulet, Laurent and Danese, Silvio and Rubin, David T and Laurent, Olivier and Luo, Allison and Nguyen, Deanna D and Lu, Jiandong and Yen, Mark and Leszczyszyn, Jaroslaw and Kempiński, Radosław and McGovern, Dermot P B and Ma, Christopher and Ritter, Timothy E and Targan, Stephan and ARTEMIS-UC Study Group, ARTEMIS-UC Study Group},
title = {Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis},
journal = {New England Journal of Medicine},
year = {2024},
volume = {391},
number = {12},
pages = {1119--1129},
doi = {10.1056/nejmoa2314076}
}
EUVIMED